January 13th 2022
By Tony Hagen
Ford Motor saved $5 million by switching patients to 5 biosimilars, and other manufacturers and employers in Michigan have achieved good results with switching programs, the Economic Alliance of Michigan reports.
January 11th 2022
Amgen Chairman and CEO Robert Bradway touted the potential of 11 biosimilars anticipated to be driving revenues for the company by 2030.
By Meir Rinde, MS
In a recent paper, Sarfaraz K. Niazi, PhD summarizes some of his central ideas on the relevance of FDA biosimilar testing standards.
January 8th 2022
In India, an emphasis on outdated biosimilar testing has restricted market entry of these products and discouraged manufacturers, patient advocates contend.
January 5th 2022
By Deana Ferreri, PhD
A comparative study of PanGen Biotech’s epoetin alfa biosimilar candidate PDA10 and the reference product, Retacrit, demonstrated comparable efficacy and safety.
January 4th 2022
Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.
January 3rd 2022
Patients with stage IV nonsquamous non–small cell lung cancer (NSCLC) demonstrated equivalent outcomes when treated with MYL-1402O or Avastin.
January 1st 2022
Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.
December 24th 2021
With fewer of the risks associated with novel drug development, biosimilar candidates allow manufacturers to plan far into the future for marketing needs.
December 23rd 2021
In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.
